FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*				2. Issuer Name and Ticker or Trading Symbol BIOSANTE PHARMACEUTICALS INC [5. Relationship of Reporting Person(s) to Issuer (Check all applicable)																		
SIMES STEPHEN M					BPAX 1									X I	Director	10% Owner		vner				
(Last) (First) (Middle)				_	-									\dashv	X Officer below)		(give title Other (below)		pecify			
111 BARCLAY BOULEVARD						3. Date of Earliest Transaction (Month/Day/Year) 01/25/2012									V	Vice Chairman, President & CEO				EO		
					4.1	If Amendment, Date of Original Filed (Month/Day/Year)									6. II	6. Individual or Joint/Group Filing (Check Applicable						
(Street)	NSHIRE II	Γ.	60069							•					Line	,	Form file	nd by One	Dono	rting Dorcer		
LINCOLNSHIRE IL 60069			,											X Form filed by One Reporting Person Form filed by More than One Reporting								
(City)	(S	tate)	(Zip)												Person							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,			Transaction Disp Code (Instr. 5)		Dispose	urities Acquired (A) sed Of (D) (Instr. 3, 4					ly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
									Ī	Code	v	Amount		(A) or (D)	Price	Trans		orted saction(s) r. 3 and 4)			(Instr. 4)	
Common Stock							7								202,167			I	By Trust			
Common Stock															100			I	By Child			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, if any		Co	4. Transaction Code (Instr. 8)		5. Number of Derivative		Exp	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		es Security	8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Co	ode	v	(A)	(D)	Dat	te ercisable		xpiration ate	Title		Amount or Number of Shares			(Instr. 4)				
Employee Stock Option (right to buy)	\$0.6844	01/25/2012			A		800,000			(1)	0:	1/24/2022	Com		800,000		\$0	800,00	00	D		

Explanation of Responses:

1. This option vests with respect to 200,000 shares on each of January 25, 2013, January 25, 2014, January 25, 2015 and January 25, 2016.

/s/ Stephen M. Simes

01/26/2012

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.